AllRock Bio Begins Patient Dosing in Phase IIa ROCSTAR Trial

Why It Matters

The trial marks a critical step toward an oral, once‑daily therapy that could complement existing PH treatments and address underlying vascular remodeling, potentially improving outcomes for PAH and ILD‑PH patients.

Key Takeaways

• First patient dosing begins in AllRock's Phase IIa ROCSTAR trial
• ROC-101 targets ROCK1/2 to reduce vascular remodeling in PH
• Trial enrolls up to 30 PAH and 10 ILD‑PH patients
• Primary endpoint: pulmonary vascular resistance change at 24 weeks
• Combines ROC‑101 with sotatercept and standard PH therapy

Pulse Analysis

Pulmonary hypertension remains a high‑mortality disease despite advances in injectable and infusion therapies. Oral agents that can modulate the underlying pathobiology are scarce, leaving a gap for treatments that address both vasoconstriction and vascular remodeling. AllRock Bio’s ROC‑101, a pan‑ROCK inhibitor, blocks ROCK1 and ROCK2 enzymes implicated in inflammation, proliferation, and fibrosis, offering a mechanistic approach that could synergize with current vasodilators and disease‑modifying agents.

The ROCSTAR Phase IIa trial is designed as an exploratory, open‑label study across multiple sites, targeting up to 30 PAH and 10 ILD‑PH patients in WHO functional class II‑III. By pairing ROC‑101 with standard‑of‑care regimens—and in a dedicated arm, with the novel agent sotatercept—researchers aim to evaluate additive benefits on hemodynamics. The primary efficacy readout, change in pulmonary vascular resistance at week 24, directly reflects the drug’s capacity to ease right‑ventricular afterload, while secondary outcomes such as six‑minute walk distance and NT‑proBNP provide functional and biomarker perspectives.

If ROC‑101 demonstrates safety and a meaningful reduction in vascular resistance, it could reshape the PH therapeutic landscape by offering a convenient oral option that tackles disease mechanisms beyond vasodilation. Investors and clinicians alike will watch the trial’s interim data for signals of efficacy, as successful results could accelerate regulatory pathways and broaden AllRock’s pipeline. Moreover, the combination strategy with sotatercept may set a precedent for multi‑modal regimens, potentially improving long‑term survival and quality of life for patients burdened by this progressive condition.